We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Ignyta

News List

Roche to buy Ignyta for $1.7 billion pharmatimes
January 03, 2018
Roche has announced plans to buy US group Ignyta for $27 a share in an all-cash deal totaling around $1.7 billion, securing itself access to the latter’s experimental cancer medicines.
Roche to Acquire Ignyta in $1.7B Deal contractpharma
December 28, 2017
Roche has entered an agreement to acquire Ignyta, Inc., a U.S. based pharmaceutical company focused on developing cancer therapies, for $1.7 billion. The acquisition expands Roche’s oncology portfolio globally.
Roche and Ignyta signs merger agreement biospectrumasia
December 26, 2017
The merger agreement has been unanimously approved by the boards of Ignyta and Roche
Ignyta's cancer drug entrectinib receives FDA orphan drug status pharmaceutical-technology
July 12, 2017
Biotechnology firm Ignyta has received orphan drug designation from the US Food and Drug Administration (FDA) for its investigational, orally available, CNS-active tyrosine kinase inhibitor, entrectinib, to treat NTRK fusion-positive solid tumours.